Non-vitamin K antagonist oral anticoagulants (NOACs) versus warfarin in patients with atrial fibrillation and (morbid) obesity or low body weight: a systematic review …

M Grymonprez, TL De Backer, S Steurbaut… - Cardiovascular Drugs and … - Springer
Purpose Oral anticoagulants are crucial for preventing systemic thromboembolism in atrial
fibrillation (AF), with guidelines preferring non-vitamin K antagonist oral anticoagulants …
被引用次数：14 相关文章

Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation and (Morbid) Obesity or Low Body Weight: a Systematic …

M Grymonprez, TL De Backer… - … Drugs and Therapy, 2022 - search.proquest.com
Purpose Oral anticoagulants are crucial for preventing systemic thromboembolism in atrial
fibrillation (AF), with guidelines preferring non-vitamin K antagonist oral anticoagulants …

Non-vitamin K antagonist oral anticoagulants (NOACs) versus warfarin in patients with atrial fibrillation and (morbid) obesity or low body weight: a systematic review …

M Grymonprez, T De Backer, S Steurbaut… - CARDIOVASCULAR …, 2022 - biblio.ugent.be
Purpose: Oral anticoagulants are crucial for preventing systemic thromboembolism in atrial
fibrillation (AF), with guidelines preferring non-vitamin K antagonist oral anticoagulants …

Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation and (Morbid) Obesity or Low Body Weight: a Systematic …

M Grymonprez, TL De Backer, S Steurbaut… - … Drugs and Therapy, 2021 - europepmc.org
Purpose Oral anticoagulants are crucial for preventing systemic thromboembolism in atrial
fibrillation (AF), with guidelines preferring non-vitamin K antagonist oral anticoagulants …

Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation and (Morbid) Obesity or Low Body Weight: a Systematic …

M Grymonprez, TL De Backer… - … Drugs and Therapy, 2022 - researchportal.vub.be
PURPOSE: Oral anticoagulants are crucial for preventing systemic thromboembolism in
atrial fibrillation (AF), with guidelines preferring non-vitamin K antagonist oral anticoagulants …

Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation and (Morbid) Obesity or Low Body Weight: a Systematic …

M Grymonprez, T de Backer, S Steurbaut… - … Drugs and Therapy, 2021 - repub.eur.nl
Purpose: Oral anticoagulants are crucial for preventing systemic thromboembolism in atrial
fibrillation (AF), with guidelines preferring non-vitamin K antagonist oral anticoagulants …

Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation and (Morbid) Obesity or Low Body Weight: a Systematic …

M Grymonprez, TL De Backer… - … Drugs & Therapy, 2022 - search.ebscohost.com
Purpose: Oral anticoagulants are crucial for preventing systemic thromboembolism in atrial
fibrillation (AF), with guidelines preferring non-vitamin K antagonist oral anticoagulants …

Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation and (Morbid) Obesity or Low Body Weight: a Systematic …

M Grymonprez, TL De Backer… - … drugs and therapy, 2022 - pubmed.ncbi.nlm.nih.gov
Purpose Oral anticoagulants are crucial for preventing systemic thromboembolism in atrial
fibrillation (AF), with guidelines preferring non-vitamin K antagonist oral anticoagulants …